EXEL will get swept down with the rest of the market but will recover faster as long as there are no company specific issues that take it off course. The stock has shown a remarkable resilience/momentum recently due to favorable developments discussed I see this as an opportunity to buy selectively adding to core positions
Leerink Partners analyst, Michael Schmidt reiterated his Outperform rating on Exelixis (NASDAQ: EXEL) following publication of American Society of Clinical Oncology (ASCO) abstracts. No change to Outperform rating or $8 price target. http://wwwDOTstreetinsiderDOTcom/Analyst+Comments/Exelixis+Inc+%28EXEL%29%3A+ASCO+Abstracts+Highlight+EXELs+TKI+Assets+-+Leerink/11651999.html
Today Leerink analyst Michael Schmidt maintained an Outperform rating on Exelixis' (EXEL)
shares after the FDA announced approval of Eisai's (ESALY) lenvatinib in combination
with Afinitor " The analyst reiterates $8 price target on Exelixis'
shares" Buying opportunity